Results 31 to 40 of about 23,013 (189)

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial

Arthritis Research & Therapy, 2023
Background Leucovorin (folinic acid) is a commonly used antidote for severe toxicity with low-dose methotrexate, but its optimum dose is unclear, varying from 15 to 25 mg every 6-h.
Mudit Bhargava, Chirag Rajkumar Kopp, Shankar Naidu, Deba Prasad Dhibar, Atul Saroch, Alka Khadwal, Tarun Narang, Siddharth Jain, Aastha Khullar, Bidya Leishangthem, Aman Sharma, Susheel Kumar, Shefali Sharma, Sanjay Jain, Varun Dhir   +14 more
doaj   +1 more source

Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
This study aimed to determine whether immuno‐nutritional and inflammatory markers could serve as predictors of the outcomes of postoperative adjuvant chemotherapy for stage III colorectal cancer in elderly patients. Postoperative lymphocyte‐to‐monocyte ratio and postoperative C‐reactive protein‐to‐albumin ratio accurately predicted the efficacy of ...
Tomoya Tago, Yasuyuki Takamizawa, Takeharu Kato, Hiroshi Nagata, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu   +6 more
wiley   +1 more source

Misinterpretation of Prescription Leading to Acute Methotrexate Toxicity: An avoidable Accident [PDF]

Liaquat National Journal of Primary Care
Low-dose oral methotrexate (MTX), as used for several dermatological and rheumatological indications, is generally a safe medication. Overdose of MTX may cause acute toxicity, which results in oral mucositis, skin ulceration, and pancytopenia.
Farhana Quyum, M.A. Bashar, Mashfiqul-Hasan   +2 more
doaj   +1 more source

Christmas Tree-Shaped Microneedles as FOLFIRINOX Spatiotemporal Delivery System for Pancreatic Cancer Treatment

Research, 2022
As an effective combination chemotherapy, FOLFIRINOX regimen (fluorouracil, leucovorin, irinotecan, and oxaliplatin) has shown definite antitumor efficacy for treating pancreatic cancer (PC) nowadays. However, the traditional systematic administration of
Danqing Huang, Xiao Fu, Xiaoxuan Zhang, Yuanjin Zhao   +3 more
doaj   +1 more source

Multidisciplinary Treatment for Esophagogastric Junction Cancer From a Dutch Perspective

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ ...
Hidde C. G. Overtoom, Suzanne S. Gisbertz   +1 more
wiley   +1 more source

Pharmacokinetics of rac‐leucovorin vs [S]‐leucovorin in patients with advanced gastrointestinal cancer. [PDF]

British Journal of Clinical Pharmacology, 1994
1. The pharmacokinetics of [R]‐leucovorin ([R]‐LV), [S]‐leucovorin ([S]‐ LV) and the circulating metabolite [S]‐5‐methyltetrahydrofolate ([S]‐5‐ MTHF) were studied after administration of racemic LV and [S]‐LV in 21 subjects. 2. After intravenous infusion of 600 mg m‐2 rac‐LV (group 1, n = 7) or 300 mg m‐2 [S]‐LV (group 3, n = 7), the decay of [S]‐LV ...
R M, Mader, G G, Steger, B, Rizovski, A E, Sieder, G, Locker, M F, Gnant, R, Jakesz, H, Rainer   +7 more
openaire   +2 more sources

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Repurposing Leucovorin for Mild Traumatic Brain Injury: Evidence from Biochemical and Behavioral Outcomes in Rats

Pharmaceuticals
Background/Objectives: Mild traumatic brain injury (mTBI) is common and may result in persistent cognitive and affective disturbances driven, at least in part, by delayed secondary injury mechanisms, including oxidative stress, neuroinflammation ...
Erdem Arslan, Melike Ordu
doaj   +1 more source

Cerebral folate deficiency, developmental difficulties in autism spectrum disorder and the role of leucovorin: a narrative review of mechanisms and clinical evidence

Drugs in Context
Cerebral folate deficiency (CFD) has recently emerged as a potentially relevant contributor to developmental difficulties in a subset of individuals with autism spectrum disorder (ASD).
Krittisak Anuroj
doaj   +1 more source